The analysis drew on Japan’s Diagnosis Procedure Combination database, a nationwide inpatient system that included more than 1,200 acute-care hospitals as of April 2024, including all 82 university hospitals. The study population comprised adults who underwent an initial hepatic resection without biliary reconstruction between January 2014 and March 2022. Patients were assigned to the drain group when a prophylactic intra-abdominal drain was placed on the day of surgery and to the no-drain group otherwise. Drain use was widespread: 62,934 patients, or 85.5% of the cohort, received a drain, while 10,679 did not. Procedures included major and minor resections performed through open, laparoscopic or robot-assisted approaches.

Before adjustment, the groups differed in several clinically relevant ways. Major hepatectomy was more common among patients who received drains, accounting for 20.5% of that group compared with 11.1% of the no-drain group. Minimally invasive surgery was more frequent among patients without drains, at 54.0% versus 31.7%. The drain group also had longer anesthesia and more intraoperative transfusions. To address these imbalances, the researchers used propensity score overlap weighting with patient, procedural and institutional variables that included age, sex, body mass index, smoking history, functional status, comorbidity, liver disease, tumor category, extent of resection, surgical approach, anesthesia time, transfusion, teaching-hospital status, annual hepatectomy volume and fiscal year. After weighting, all measured covariates were considered balanced using an absolute standardized difference threshold below 0.10.

The primary endpoint was postoperative intra-abdominal infection, defined for the study as bile leakage, intra-abdominal abscess or pancreatic fistula. In the weighted comparison, infection occurred in 5.1% of the drain group and 5.5% of the no-drain group. The estimated risk difference was −0.3 percentage points, with a 95% confidence interval of −0.8 to 0.1, and was not statistically significant. Bile leakage was also similar after weighting, at 1.0% with drains and 0.9% without them, with a risk difference of 0.1 percentage points and a 95% confidence interval of −0.07 to 0.3. Neither postoperative transfusion nor postoperative ventilation for at least two days differed significantly between the groups.

In-hospital mortality showed a different statistical pattern. The weighted death rate was 0.5% among patients with drains and 1.0% among those without them, corresponding to a risk difference of −0.6 percentage points and a 95% confidence interval of −0.8 to −0.4. A sensitivity analysis used generalized estimating equations to account for patient clustering within hospitals and included 72,071 patients treated at 1,147 hospitals. This analysis again found no significant association between drain placement and intra-abdominal infection, with an odds ratio of 0.96 and a 95% confidence interval of 0.87 to 1.06. By contrast, drain placement remained associated with lower in-hospital mortality, with an odds ratio of 0.50 and a 95% confidence interval of 0.39 to 0.63.

Drain placement was associated with a slightly longer postoperative hospital stay, but the difference was small. Weighted mean postoperative stays were 14.1 days for patients with drains and 13.8 days for those without them, a difference of 0.3 days with a 95% confidence interval of 0.008 to 0.7. Total hospitalization costs did not differ significantly: the weighted means were US$10,859 with drains and US$10,848 without them, producing a difference of −US$11 and a 95% confidence interval of −US$141 to US$165. The database also showed no significant difference in postoperative drainage, which was recorded in 1.0% of the weighted drain group and 1.1% of the weighted no-drain group. Thus, the study detected no clear association between prophylactic drains and either lower costs or a shorter postoperative stay.

Exploratory subgroup analyses suggested that the statistical patterns varied with patient characteristics and institutional context. Intra-abdominal infection was significantly lower in the drain group among patients treated at high-volume hospitals, but no significant difference was detected in the low- or middle-volume categories. Mortality was significantly lower with drains among patients with a body mass index below 18.5 kg/m² or from 18.5 to 24.9 kg/m², but not among those at 25.0 to 29.9 or at least 30.0 kg/m². Lower mortality was also reported across the categories of resection extent and surgical approach, as well as in low- and middle-volume hospitals, but not in high-volume hospitals. These analyses were exploratory, did not identify which patients should receive drains and cannot establish that drain placement produced the observed subgroup differences.

One possible explanation advanced by the authors is that a drain may furnish clinicians with information that helps them identify and manage severe postoperative complications earlier, even if the device does not prevent the complication itself. The paper notes that bile leakage can progress to peritonitis or intra-abdominal sepsis and that some refractory cases require additional surgery. Established monitoring and rescue systems at high-volume hospitals might make the additional information less consequential, while differences in postoperative monitoring resources at lower-volume hospitals could make drain output more useful. These are interpretations rather than demonstrated mechanisms: the database did not record whether drains altered monitoring or treatment, and it could not identify the specific causes of death.

Several limitations constrain interpretation of the mortality association. The retrospective design permits residual confounding, particularly because the reasons for drain placement and the decisions of individual surgeons were unavailable. Information was also missing on the duration and type of drain management, which could influence postoperative outcomes. The database did not capture pain, discomfort, delayed mobilization, cosmetic impairment or injury to vessels or organs during insertion. Although the Diagnosis Procedure Combination database generally records diagnoses with high specificity, its sensitivity varies, and the study-specific algorithms used to identify bile leakage, intra-abdominal abscess and other infections had not been individually validated against medical records. Complication underestimation or misclassification therefore remains possible.

The timing data were also incomplete. The database did not provide the exact intraoperative moment when a drain was placed, so the temporal sequence among drain placement, anesthesia duration and intraoperative transfusion could not be established. Hospital type and hepatectomy volume were included in the adjustment, but unmeasured institutional policies, surgeon preferences and perioperative systems may have influenced both drain use and patient outcomes. In addition, the overlap-weighted estimates primarily represent patients for whom either drainage strategy was reasonably plausible on the basis of measured characteristics. The findings may not generalize to severely complex operations, unusual bile-leakage risk or other situations in which a clinician would almost certainly place a drain. Overall, the study found no association between prophylactic drainage and reduced intra-abdominal infection among adults undergoing hepatic resection without biliary reconstruction, while lower mortality among drain recipients remains an observational signal that requires prospective testing rather than evidence of a causal survival benefit.

Subject of Research: Associations between prophylactic abdominal drains and short-term outcomes after liver resection in Japan

Article Title: Association of Prophylactic Abdominal Drain Placement With Short‐Term Postoperative Outcomes After Hepatectomy: A Nationwide Inpatient Database Study in Japan

Article References: Kouzu, K., Aso, S., Hirano, Y., Matsui, H., Yoshimura, K., Kitagawa, H., Kato, T., Yamane, N., Hagiwara, O., Miyoshi, N., Matsuda, S., Maruyama, H., Morikane, K., Sasaki, J., Yasunaga, H., Kitagawa, Y., Watanabe, M., & Tsujimoto, H. (2026). Association of Prophylactic Abdominal Drain Placement With Short‐Term Postoperative Outcomes After Hepatectomy: A Nationwide Inpatient Database Study in Japan. Annals of Gastroenterological Surgery, Article ags3.70299. https://doi.org/10.1002/ags3.70299

Image Credits: AI Generated

DOI: 10.1002/ags3.70299

Keywords: liver resection, abdominal drains, hepatectomy, surgical infection, bile leakage, in-hospital mortality, retrospective cohort, Japanese inpatient database, hospitalization costs, patient outcomes, Association, Prophylactic

The research, conducted at Guangzhou Women and Children’s Medical Center affiliated with Guangzhou Medical University and published in Frontiers in Drug Safety and Regulation, analyzed medical records from 16,952 women who underwent repeat cesarean sections between July 2016 and December 2023. Of these, 2,777 women received prophylactic tranexamic acid intraoperatively, while the remaining 14,175 did not. Because the decision to administer the drug was left to the clinical judgment of attending obstetricians rather than a standardized protocol, the researchers faced an immediate statistical challenge: the two groups differed systematically in baseline characteristics, including rates of gestational hypertension and general anesthesia use. To address this imbalance, the team employed 1:2 propensity score matching with a caliper of 0.01, a technique that pairs each treated patient with two untreated patients who have nearly identical predicted probabilities of receiving the drug based on maternal age, pre-pregnancy body mass index, gestational age, gestational diabetes, gestational hypertensive disorders, neonatal birth weight, and other covariates.

After matching, 2,777 women in the tranexamic acid group were compared with 5,554 women in the control group, and the standardized mean differences for all covariates fell below 0.10, indicating that the matched cohorts were well balanced. The results were striking. The incidence of postpartum hemorrhage, defined as estimated blood loss of at least 1,000 milliliters within 24 hours of cesarean section or red blood cell transfusion within two days of delivery, was 11.09 percent in the tranexamic acid group compared with 17.03 percent in the control group, a difference that was highly statistically significant with a P value below 0.001. In absolute terms, this means roughly six additional cases of postpartum hemorrhage were prevented for every 100 women treated.

Secondary outcomes reinforced the primary finding. Women who received prophylactic tranexamic acid showed a smaller postpartum hemoglobin decline, with 12.06 percent experiencing a drop of at least 20 grams per liter compared with 18.44 percent in the control group. Calculated estimated blood loss categories also favored the treated group: 38.6 percent of women in the tranexamic acid group had calculated blood loss exceeding 500 milliliters, compared with 49.51 percent of controls, and only 9.94 percent exceeded 1,000 milliliters versus 15.72 percent of controls. The rate of additional uterotonic agents, specifically intramuscular carboprost tromethamine, was also lower in the treated group at 26.9 percent versus 29.8 percent, suggesting that tranexamic acid reduced the reliance on second-line, more potent uterotonics that carry greater side effect profiles.

Multivariate logistic regression, adjusting for age, gestational age, body mass index, general anesthesia, gestational hypertensive disorders, gestational diabetes, and macrosomia, confirmed that prophylactic tranexamic acid was an independent protective factor against postpartum hemorrhage, with an odds ratio of 0.620 and a 95 percent confidence interval of 0.540 to 0.712. This means that, even after accounting for measurable confounders, women who received the drug had roughly 38 percent lower odds of experiencing postpartum hemorrhage than matched controls who did not.

Notably, the study found no statistically significant difference in blood transfusion rates between the two groups, with 1.55 percent of the tranexamic acid group requiring transfusion compared with 2.09 percent of controls, a P value of 0.089. The researchers attribute this to their center’s strict adherence to restrictive transfusion thresholds, following national guidelines that recommend transfusion only when hemoglobin falls below 70 grams per liter or when symptomatic anemia is present. Because transfusions were already rare in both groups, the study lacked the statistical power to detect a difference in this particular outcome, a limitation shared with several large randomized trials of tranexamic acid in obstetrics.

Tranexamic acid is an antifibrinolytic agent that works by blocking the conversion of plasminogen to plasmin, thereby inhibiting the breakdown of fibrin clots. In trauma surgery and other bleeding scenarios, the drug has demonstrated mortality benefits in landmark trials such as CRASH-2. In obstetrics, the World Health Organization recommends early intravenous tranexamic acid for patients with confirmed postpartum hemorrhage, but the evidence for prophylactic use during cesarean section has been more complex and evolving. While numerous small-to-medium-sized randomized controlled trials and meta-analyses have suggested that the drug reduces blood loss and transfusion requirements, the certainty of this evidence has been graded as low due to serious limitations in trial design and reporting. More importantly, recent large-scale pragmatic randomized trials have yielded mixed or null findings regarding clinically significant outcomes.

The TRAAP2 trial, a multicenter double-blind randomized controlled trial involving over 11,000 women undergoing cesarean delivery, found that while tranexamic acid reduced a composite outcome of calculated blood loss exceeding 1,000 milliliters or red cell transfusion, it did not significantly reduce the need for additional uterotonics or other clinically relevant hemorrhagic morbidity. Another major randomized trial similarly found no significant reduction in a composite of hemorrhage-related outcomes with prophylactic tranexamic acid. The new Chinese cohort study, focused specifically on the repeat cesarean subgroup, found reductions in both calculated blood loss and additional uterotonic use, a discrepancy the researchers attribute to population specificity. Women with prior uterine scars face heightened bleeding risk from both uterine atony and surgical wound oozing, and tranexamic acid’s antifibrinolytic action may be particularly effective against the latter mechanism, potentially yielding greater relative benefit in this subgroup than in an unselected cesarean population.

Safety considerations are paramount when evaluating any prophylactic intervention in pregnancy. The researchers observed no thromboembolic events in their cohort, consistent with the short-term safety profile reported in many studies of tranexamic acid. However, they caution that the retrospective nature of the study, the lack of active surveillance for thromboembolism, and the relatively low incidence of these events in the general obstetric population limit their ability to draw definitive conclusions about safety. Large trials have reported small numerical increases in thromboembolic events with tranexamic acid, as well as increased incidences of non-thromboembolic adverse effects such as nausea and vomiting, which retrospective data did not capture. The researchers emphasize that ongoing vigilance and prospective safety data collection, specifically in high-risk obstetric subgroups, remain essential.

The study also noted a counterintuitive finding: a significantly higher rate of severe hemorrhage-related interventions, including arterial embolization, hysterectomy, or emergency surgery, in the tranexamic acid group at 0.5 percent versus 0.18 percent in controls. The researchers propose that this may be a statistical artifact due to the very small number of events, or that when postpartum hemorrhage did occur in the treated group, it may have been more severe or refractory to medical management. Given the small numbers involved, they emphasize that this finding should be considered hypothesis-generating and requires further investigation in larger, prospective studies. The authors conclude that prophylactic tranexamic acid was associated with a lower incidence of postpartum hemorrhage and reduced need for additional uterotonics in women undergoing repeat cesarean sections, and they call for dedicated randomized controlled trials in this specific high-risk population to confirm these hypothesis-generating findings.

Subject of Research: Maternal-Fetal Medicine

Article Title: Efficacy of prophylactic tranexamic acid in preventing postpartum hemorrhage following repeat cesarean sections: a retrospective matched-cohort study

Article References: Di, X., Li, X., Zheng, Z., Guo, L., Dong, T., & Chen, Q. (2026). Efficacy of prophylactic tranexamic acid in preventing postpartum hemorrhage following repeat cesarean sections: a retrospective matched-cohort study. Frontiers in Drug Safety and Regulation, 6, Article 1911287. https://doi.org/10.3389/fdsfr.2026.1911287

Image Credits: AI Generated

DOI: 10.3389/fdsfr.2026.1911287

Keywords: tranexamic acid, postpartum hemorrhage, repeat cesarean section, propensity score matching, maternal health, obstetrics, antifibrinolytic, Frontiers in Drug Safety and Regulation, Efficacy, prophylactic, tranexamic, acid

The retrospective cohort study, led by Stefani M. Doucette and senior author Abhay Lodha, examined the records of 676 extremely preterm infants born at less than 29 weeks’ gestational age. The researchers compared outcomes before and after their units introduced routine prophylactic arginine supplementation during the first 28 days of life. The primary outcome was bronchopulmonary dysplasia, defined as a continuing need for oxygen at 36 weeks’ postmenstrual age, with severity classified according to the evidence-based criteria developed by Jensen and colleagues. What the team found was striking: the incidence of any bronchopulmonary dysplasia fell from 85 percent to 73 percent after routine supplementation began, a drop of twelve percentage points in a population where nearly every infant had previously been expected to develop some degree of the disease.

Because a before-and-after comparison can be confounded by concurrent changes in care, the investigators went beyond raw numbers. Using multivariable regression analysis to adjust for other factors that influence lung outcomes, they calculated an adjusted odds ratio of 0.50 for any bronchopulmonary dysplasia, with a 95 percent confidence interval of 0.27 to 0.90. In practical terms, even after accounting for other variables, infants exposed to prophylactic arginine had roughly half the odds of developing the disease compared with those who did not receive it. The composite outcome of bronchopulmonary dysplasia or death before 36 weeks’ postmenstrual age was similarly reduced, with an adjusted odds ratio of 0.51 and a confidence interval of 0.28 to 0.91, suggesting that the benefit was not simply an artifact of shifting survival patterns.

Yet the story is not one of unqualified triumph. When the researchers looked specifically at severe disease, grades 2 and 3 on the Jensen scale, the protective signal disappeared. The adjusted odds ratio for severe bronchopulmonary dysplasia was 0.94, with a confidence interval spanning 0.41 to 2.14, a range that includes no effect at all. This pattern suggests that arginine supplementation may primarily prevent milder forms of the disease, or that the study, despite its respectable size, lacked the statistical power to detect a benefit against the most serious outcomes. The distinction matters enormously for families and clinicians, because severe disease carries the heaviest burden of long-term respiratory morbidity, neurodevelopmental impairment, and healthcare cost.

To understand why an amino acid might influence lung development at all, one has to look at the biochemistry of nitric oxide. L-arginine is the obligate substrate for nitric oxide synthase, the enzyme family that converts arginine into nitric oxide, a gaseous signaling molecule with profound effects on vascular tone. In the developing lung, nitric oxide promotes vasodilation of the pulmonary vasculature, supports endothelial function, and helps coordinate the intricate angiogenic crosstalk between blood vessels and the forming air sacs. Extremely preterm infants are known to have low circulating arginine levels, partly because arginine is consumed rapidly by the urea cycle and by arginase enzymes, and partly because the pathways that normally synthesize it are immature. When arginine availability falls, nitric oxide production falters, and the pulmonary vessels that should be remodeling and expanding instead constrict and develop abnormally.

This mechanistic framework is supported by decades of animal research. Studies in hyperoxia-exposed newborn rodents, a standard model of bronchopulmonary dysplasia, have shown that impaired nitric oxide signaling contributes to arrested alveolar growth and pulmonary vascular remodeling, and that restoring downstream intermediates such as L-citrulline can attenuate these injuries. Depletion of arginine by overactive arginase has been implicated in impaired relaxation of lung parenchyma in exposed neonatal animals. Clinical observations add further weight: neonates with pulmonary hypertension have been found to have abnormalities in urea-cycle intermediates and reduced nitric oxide production, linking arginine metabolism directly to pulmonary vascular disease in human newborns.

The arginine hypothesis also fits within a broader, and somewhat humbling, therapeutic history. Inhaled nitric oxide, the direct administration of the very molecule that arginine helps produce, has been tested extensively in preterm infants as a potential preventive therapy for bronchopulmonary dysplasia. Multiple randomized trials and an individual-patient-data meta-analysis failed to demonstrate a consistent benefit, and recent masked randomized controlled trials targeting early pulmonary hypertension have continued to yield uncertain results. The apparent failure of inhaled nitric oxide has pushed researchers toward upstream and systemic approaches, including enteral arginine supplementation, which is cheaper, easier to administer, and may support nitric oxide production throughout the body rather than only in the ventilated airways.

Interestingly, this is not the first time arginine has shown promise in neonatology. Earlier clinical work by some of the same Calgary investigators demonstrated that arginine supplementation could reduce the incidence of necrotizing enterocolitis, a devastating intestinal disease of prematurity, and an updated systematic review has supported that association. The common thread is nitric oxide biology: in the gut, nitric oxide maintains mucosal blood flow and barrier integrity, while in the lung it supports vascular and alveolar development. Arginine’s role as a shared substrate for these protective pathways has made it an attractive candidate for multi-target prophylaxis in the smallest infants, and the new findings extend that logic from the intestine to the lung.

The authors and independent observers alike caution that a retrospective, single-center before-and-after design cannot establish causation. Secular trends in neonatal care, including evolving ventilation strategies, caffeine use, surfactant protocols, and nutrition practices, could have contributed to the observed decline in disease rates, even with statistical adjustment. The study was approved by the Conjoint Health Research Ethics Board at the University of Calgary with a waiver of informed consent, and the authors declare no competing interests, but the inherent limitations of observational methodology mean that a randomized controlled trial remains the essential next step. Such a trial would need to be powered to detect effects on severe disease and long-term respiratory outcomes, not merely the milder spectrum of the condition.

Nevertheless, the implications of the study are considerable. Bronchopulmonary dysplasia remains one of the most common and consequential morbidities of extreme prematurity, imposing enormous healthcare burdens through prolonged hospitalization, home oxygen therapy, readmissions, and increased mortality in outpatient populations. If a randomized trial confirms the association reported here, neonatal intensive care units would gain a remarkably low-cost, orally administered preventive therapy that could be folded into existing feeding protocols for infants under 29 weeks. For now, the Calgary findings offer something rarer than a cure: a biologically plausible, mechanistically grounded lead in a field where genuine therapeutic advances have been scarce, and a reminder that sometimes the most powerful medicines are the humblest molecules already present in the body’s own chemistry.

Subject of Research: Prophylactic arginine supplementation to prevent bronchopulmonary dysplasia in extremely preterm infants

Article Title: The role of prophylactic arginine supplementation for prevention of bronchopulmonary dysplasia in extremely preterm infants

Article References: Doucette, S. M., Jain, S. K., Amin, H., Benlamri, A., Hussain, M., Tang, S., Bhandari, V., & Lodha, A. (2026). The role of prophylactic arginine supplementation for prevention of bronchopulmonary dysplasia in extremely preterm infants. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02922-4

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02922-4

Keywords: arginine supplementation, bronchopulmonary dysplasia, extremely preterm infants, nitric oxide, neonatology, retrospective cohort study, pulmonary vascular development, chronic lung disease, prematurity, Journal of Perinatology, role, prophylactic

Bronchopulmonary dysplasia, or BPD, is a chronic lung disease that develops when the fragile, immature lungs of very preterm infants are damaged by mechanical ventilation, oxygen therapy, and inflammation during the first weeks of life. Infants who develop BPD often require prolonged respiratory support and hospitalization, and they face elevated risks of rehospitalization, neurodevelopmental impairment, and long-term respiratory problems such as asthma-like symptoms and reduced lung function well into childhood and adulthood. Because survival rates for extremely preterm infants have climbed steadily over recent decades, BPD has become one of the most common long-term consequences of prematurity, making effective prevention strategies a major priority for neonatal medicine.

Caffeine is already a workhorse of neonatal care. A methylxanthine compound that crosses the blood-brain barrier readily, caffeine acts primarily as a respiratory stimulant by antagonizing adenosine receptors in the brainstem, increasing the drive to breathe and improving diaphragmatic contractility. Since a landmark 2006 international trial demonstrated that caffeine therapy shortened the duration of mechanical ventilation and reduced the rate of BPD among extremely low-birth-weight infants, caffeine citrate has become standard treatment for apnea of prematurity in neonatal intensive care units worldwide. However, that trial initiated caffeine only once apnea developed or clinicians judged treatment necessary—what neonatologists call therapeutic administration. Whether giving the drug prophylactically, within hours of birth to all very preterm infants regardless of symptoms, could prevent BPD more effectively remained unresolved, and prior smaller studies had produced mixed and inconclusive results.

To address this gap, researchers led by Fangfang Tao and Jiang-Qin Liu of Shanghai First Maternity and Infant Hospital, together with colleagues at Children’s Hospital of Fudan University and the University of Alberta, enrolled 372 very preterm neonates born before 32 weeks and 0 days of gestation between September 2016 and January 2024. In this single-center, randomized clinical trial, infants were assigned to one of two strategies. The prophylactic caffeine administration group received caffeine citrate shortly after birth, beginning with a loading dose of 20 milligrams per kilogram of body weight followed by a daily maintenance dose of 10 milligrams per kilogram. The comparison group received therapeutic caffeine administration, meaning the same drug at the same doses, but only after a diagnosis of apnea was made. The primary endpoint was the composite of BPD at 36 weeks postmenstrual age and/or death before hospital discharge.

The results favored early treatment. BPD or death occurred in 37.1 percent of infants in the prophylactic group—69 of 186 infants—compared with 47.3 percent in the therapeutic group, or 88 of 186. That difference corresponds to a relative risk of 0.77 with a 95 percent confidence interval of 0.62 to 0.95, and a P value of 0.013, meaning the reduction was statistically significant and unlikely to be due to chance alone. In practical terms, for roughly every ten very preterm infants treated prophylactically rather than reactively, one fewer infant would be expected to die before discharge or leave the hospital requiring oxygen for chronic lung disease.

The effect proved robust across five different sensitivity analysis models designed to test whether the finding depended on particular statistical assumptions. Notably, the benefit appeared more pronounced in several clinically meaningful subgroups: female infants, infants whose mothers had received antenatal corticosteroids to accelerate fetal lung maturation, infants who were not intubated in the delivery room, and infants who required only noninvasive ventilation after birth. This pattern is biologically plausible, since these are infants whose lungs were less severely compromised at the outset and who therefore stood to gain the most from protecting the airways and respiratory drive before injury could accumulate.

Caffeine’s protective mechanism in the context of BPD is thought to extend beyond simple respiratory stimulation. Experimental work suggests that caffeine exerts anti-inflammatory effects, modulates cytokine responses, improves diaphragmatic and intercostal muscle function, and enhances respiratory pattern stability, all of which can reduce the need for invasive mechanical ventilation and high oxygen concentrations—the principal drivers of lung injury in preterm infants. By stabilizing breathing from the first hours of life, prophylactic caffeine may prevent the cascade of apnea episodes, desaturations, and escalation of ventilatory support that culminates in chronic lung disease.

The trial was not without signals of potential harm, and the authors were careful to report them. Infants in the prophylactic group received a higher number of blood transfusions than those in the therapeutic group, with a mean difference of 0.42 transfusions (95 percent confidence interval, 0.05 to 0.79; P = 0.027). The clinical significance of this small increase is uncertain, but it aligns with earlier observations that early caffeine use has been associated with more frequent phlebotomy-related blood sampling and transfusion in previous trials. Importantly, no significant differences were observed between the two groups in the incidence of other serious complications of prematurity, including necrotizing enterocolitis, intraventricular hemorrhage, retinopathy of prematurity, and late-onset sepsis, nor in the duration of mechanical or noninvasive ventilation, oxygen exposure, length of hospital stay, or medical costs.

The researchers emphasized that the study had limitations inherent to its design. As a single-center trial, its findings may reflect the specific practices and patient population of one institution, and confirmation in multicenter settings is needed before the results can be generalized universally. The trial was registered retrospectively in the Chinese Clinical Trial Registry, a point the authors acknowledged transparently. In addition, the composite primary outcome of BPD or death, while standard in neonatal trials, combines two distinct events, and a larger sample would be required to separately power each component. Still, the trial’s seven-and-a-half-year enrollment window, its randomized design, and the consistency of the effect across sensitivity analyses lend considerable weight to the conclusion.

For neonatologists, the study raises the prospect of shifting practice: rather than waiting for apnea to declare itself, starting caffeine citrate routinely within the first hours of life in infants born before 32 weeks could prevent a substantial share of BPD cases and deaths. Prophylactic caffeine is already inexpensive, well tolerated, and familiar to every neonatal unit, which means that if the findings are confirmed, implementation barriers would be minimal compared with entirely new therapies. As BPD continues to burden a growing population of preterm survivors, an intervention this simple—administering earlier a drug already sitting in the NICU pharmacy—represents exactly the kind of low-cost, high-reach strategy that could reshape outcomes for the most vulnerable newborns. The study was funded through the CHINA-CANADA Clinical Research program, and the full open-access article is available in BMC Pediatrics.

Subject of Research: Prophylactic caffeine administration to prevent bronchopulmonary dysplasia in very preterm infants

Article Title: Prophylactic administration of caffeine reduces bronchopulmonary dysplasia in very preterm infants: a single center, randomized controlled trial

Article References: Tao, F., Zhou, M., Fu, Y., Zhou, J., Wang, M., Duan, Y., Li, M., Hua, J., Wang, Y., Chen, C., Cheung, P.-Y., Yuan, L., Yan, W., & Liu, J.-Q. (2026). Prophylactic administration of caffeine reduces bronchopulmonary dysplasia in very preterm infants: a single center, randomized controlled trial. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07625-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07625-5

Keywords: caffeine, bronchopulmonary dysplasia, very preterm infants, prophylactic administration, randomized controlled trial, apnea of prematurity, neonatal intensive care, caffeine citrate, chronic lung disease, mechanical ventilation, Prophylactic, administration